The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model: NEW TECHNOLOGIES

Journal of Interventional Cardiology

Volumn 22, Issue 5, 2009, Pages 466-478

  Huang, Yingying ^a   Venkatraman, Subbu S ^a   Boey, Freddy Y C ^a   Umashankar, P R ^b   Mohanty, Mira ^b   Arumugam, Sabareeswaran ^c  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b Division of In vivo Models and Testing

^c SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CHROMIUM; CLOPIDOGREL; COBALT; CYPHER; HEPARIN; NADROPARIN; POLYMER; RAPAMYCIN; TRIFLUSAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART FIBRILLATION; IN VITRO STUDY; IN VIVO STUDY; IN-STENT RESTENOSIS; INHIBITION KINETICS; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; STENT THROMBOSIS; THROMBOGENESIS;

ANIMALS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CHROMIUM ALLOYS; CORONARY RESTENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; IMMUNOSUPPRESSIVE AGENTS; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; SALICYLATES; SIROLIMUS; SWINE; THROMBOSIS; TREATMENT OUTCOME;

EID: 70349747090     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2009.00489.x     Document Type: Article

References (43)

1. Waksman R. Drug-eluting stents: From bench to bed. Cardiovasc Radiat Med 2002 3 : 226 241.
2. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001 59 : 227 248.
3. Gunn J, Cumberland D. Stent coatings and local drug delivery. State of the art. Eur Heart J 1999 20 : 1693 1700.
4. Garas SM, Huber P, Scott NA. Overview of therapies for prevention of restenosis after coronary interventions. Pharmacol Ther 2001 92 : 165 178.
5. Rajagopal V, Rockson SG. Coronary restenosis: A review of mechanisms and management. Am J Med 2003 115 : 547 553.
6. Bennett MR, O'Sullivan M. Mechanisms of angioplasty and stent restenosis: Implications for design of rational therapy. Pharmacol Ther 2001 91 : 149 166.
7. Kivelä A, Hartikainen J. Restenosis related to percutaneous coronary intervention has been solved? Ann Med 2006 38 : 173 187.
8. Tsuchida K, Serruys PW, Bruining N, et al. Two-year serial coronary angiographic and intravascular ultrasound analysis of in-stent angiographic late lumen loss and ultrasonic neointimal volume from the TAXUS II trial. Am J Cardiol 2007 99 : 607 615.
9. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: Long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002 106 : 1610 1613.
10. Venkatraman S, Boey F. Release profiles in drug-eluting stents: Issues and uncertainties. J Control Release 2007 120 : 149 160.
11. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: Balancing the reduction in restenosis with the concern of late thrombosis. Lancet 2008 371 : 2134 2143.
12. Tsimikas S. Drug-eluting stents and late adverse clinical outcomes: Lessons learned, lessons awaited. J Am Coll Cardiol 2006 47 : 2112 2115.
13. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003 108 : 788 794.
14. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J Am Coll Cardiol 2004 44 : 1373 1385.
15. Gautam Kedia MSL. Stent thrombosis with drug-eluting stents: A re-examination of the evidence. Catheter Cardiovasc Interven 2007 69 : 782 789.
16. Tina L, Pinto Slottow RW. Overview of the 2006 Food and Drug Administration circulatory system devices panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interven 2007 69 : 1064 1074.
17. Meredith KG, Badger RS, Tandar A, et al. Stent thrombosis in the modern drug-eluting stent era compared to the bare-metal stent era: A comparison from a large clinical registry. J Am Coll Cardiol 2007 49 : B1 B46.
18. Ong ATL, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005 45 : 947 953.
19. Richter GM, Palmaz JC, Noeldge G, et al. Relationship between blood flow, thrombus, and neointima in stents. J Vasc Interv Radiol 1999 10 : 598 604.
20. Mehran R, Aymong ED, Ashby DT, et al. Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: Final results of the HOPE (HEPACOAT and an antithrombotic regimen of aspirin alone) study. Circulation 2003 108 : 1078 1083.
21. Whelan DM, Van Der Giessen WJ, Krabbendam SC, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000 83 : 338 345.
22. Lee Y-K, Hyung Park J, Tae Moon H, et al. The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer. Biomaterials 2007 28 : 1523 1530.
23. Cho H-Y, Jeong T-J, Lee Y-B. Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. J Chromatogr B 2003 798 : 257 264.
24. Gema R, Gallardo A, Fernández M, et al. Hydrophilic polymer drug from a derivative of salicylic acid: Synthesis, controlled release studies and biological behavior. Macromol Biosci 2004 2 : 579 586.
25. Peppas NA, Huang Y, Torres-Lugo M, et al. Physicochemical foundations and structural design of hydrogels in medicine and biology. Ann Rev Biomed Eng 2000 2 : 9 27.
26. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 2000 21 : 2475 2490.
27. Vert M, Suming L, Garreau H. More about the degradation of LA/GA-derived matrices in aqueous media. J Control Release 1991 16 : 15 26.
28. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary-artery injury - Results in a porcine model. J Am Coll Cardiol 1992 19 : 267 274.
29. Schwartz RS, Edelman ER. Drug-eluting stents in preclinical studies - Recommended evaluation from a consensus group. Circulation 2002 106 : 1867 1873.
30. Schulz C, Herrmann RA, Beilharz C, et al. Coronary stent symmetry and vascular injury determine experimental restenosis. Heart 2000 83 : 462 467.
31. Sullivan TM, Ainsworth SD, Langan EM, et al. Effect of endovascular stent strut geometry on vascular injury, myointimal hyperplasia, and restenosis. J Vasc Surg 2002 36 : 143 149.
32. Celik T, Iyisoy A, Barindik N, et al. Glucocorticoids in the prevention of in-stent restenosis: The role of inflammation. Int J Cardiol, in press, corrected proof.
33. Kim JY, Ko YG, Shim CY, et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005 96 : 1384 1388.
34. Rogers C, Welt FGP, Karnovsky MJ, et al. Monocyte recruitment and neointimal hyperplasia in rabbits - Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996 16 : 1312 1318.
35. Welt FGP, Edelman ER, Simon DI, et al. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol 2000 20 : 2553 2558.
36. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001 104 : 1188 1193.
37. Nakazawa G, Finn AV, John MC, et al. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007 100 : 36M 44M.
38. Kereiakes DJ, Cox DA, Hermiller JB, et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003 92 : 463 466.
39. Hong MK, Kornowski R, Bramwell O, et al. Paclitaxel-coated Gianturco-Roubin (R) IIAl (GR (R) II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coronary Art Dis 2001 12 : 513 515.
40. Jabara R, Ollerenshaw J, Chronos N, et al. Toxic vessel reaction to an absorbable polymer-based paclitaxel-eluting stent in pig coronary arteries. Am J Cardiol 2006 98 : 210M 211M.
41. Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004 109 : 2168 2171.
42. Carter AJ, Brodeur A, Collingwood R, et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interven 2006 68 : 97 103.
43. Rodriguez G, Gallardo A, San Roman J, et al. New resorbable polymeric systems with antithrombogenic activity. J Mater Sci Mater Med 1999 10 : 873 878.